Recon: Lundbeck to Buy Parkinson’s Drug Developer; J&J Receives Bid for Diabetes Business

• Pfizer Lifts CEO's Pay 61% to $27.9 Million With Retention Bonus (Bloomberg) (Endpoints) (STAT)
• J&J says it's received a $2.1 billion bid for LifeScan diabetes business (CNBC) (Reuters) (Fierce)
• Orthofix to acquire Spinal Kinetics in deal worth up to $105M (Fierce) (MassDevice)
• Why Google co-founder Sergey Brin was using a robot to put sutures in synthetic tissue (CNBC)
• Citing risk of 'serious consequences,' Bayer pulls Alka-Seltzer boxes listing incorrect ingredients (Fierce) (Miami Herald)
• Bill Of The Month: For Toenail Fungus, A $1,500 Prescription (KHN)
• Theranos and the Problem With Booming Biotech Funding (Bloomberg)
• Five Reasons for Receiving an FDA Refuse-to-Accept (RTA) Decision on your 510(k) Registration (Emergo Group)
• Big Pharma's winners and losers last year? AbbVie and AstraZeneca up, GSK down (Fierce)

• Lundbeck to buy Parkinson's drug developer in potential $1.1 billion deal (Reuters) (Endpoints) (Fierce) (BioPharma Dive)
• NICE endorses Keytruda for bladder cancer (PharmaTimes) (The Pharma Letter-$) (PMLiVE) (Fierce)
• EMA to hold public hearing on quinolone and fluoroquinolone antibiotic safety (The Pharmaceutical Journal)
• Glaxo Sees Up to $100 Million in Initial Costs From Brexit (Bloomberg)
• With U.S. brand sales deflating, Pfizer gears up for over-the-counter Viagra in U.K. (Fierce)
• ATM pharmacy to cut queues for South Africa's AIDS patients (Reuters)
• After GSK snub, Ionis finds new commercialization partner—its own spinout (Fierce) (BioCentury) (BioSpace) (BioPharma Dive)
• Swiss Pharma Gets a Taste of Silicon Valley (Bloomberg-$)
• Another reason to visit Egypt: Europe’s high drug prices (Politico)
• On the frontlines of the fight against Lassa fever in Nigeria (WHO)

• Grassley, Leahy: It’s time to empower generic drug makers to bring down prices (STAT)
• Drug makers jostle over potential Medicare changes in congressional spending deal (STAT-$)
• Lawmakers want to remove gag clauses that boost drug costs at the pharmacy counter (STAT-$)
• Practical magic: Google counsels pharma to create 'seamless' digital experiences (Fierce)
• ICER Weekly View 03-16-18 (ICER)
• Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain (Press)
• GlaxoSmithKline chief Emma Walmsley nets $6.8M in pay in her first year at the helm (Fierce)
• Getting past the bad blood of Theranos through collaboration (STAT)
• CVS Health Applauds New Legislation to Better Inform Pharmacy Choices (Press)
• ImmunoPrecise to acquire ModiQuest Research (The Pharma Letter)
• PTAB Releases Orange Book-Listed Patent Study (Patent Law Weblog)
• Plan Sponsors Prefer Specialty Pharmacies Over Retail Drugstores (Drug Channels)
• Theranos Serves as a Cautionary Tale for Biotech Funding (BioSpace)

• FDA OK’s Hizentra for rare autoimmune disease CIPD (Endpoints)
• Adaptimmune shares boosted by new signs of success with TCR cell therapy (Endpoints)
• FDA Gives Go-Ahead for Tetra's Phase II Trial (BioSpace) (Press)
• CVS Pharmacy Now Offering New Shingles Vaccine at Locations Nationwide (Press)
• Covance forms I&I unit to meet increasing demand for biologics services (Outsourcing-Pharma)
• Zosano Reaches Enrollment Milestone In M207-Adam Long-Term Safety Study (Reuters)
• Cellular Biomedicine Announces Positive Clinical Data Of Knee Osteoarthritis China Phase I Trial (Reuters)
• Adaptimmune’s GSK-partnered T cells trigger responses in solid tumor patients (Fierce)
• Tumor-derived T-cells show promise against ovarian cancer (Fierce)
• Boehringer, Vanderbilt U to develop cancer MCL1 inhibitors in third team-up (Fierce)
• ADDMEDICA Receives FDA-Approval for Orphan Drug Siklos, First and Sole Hydroxyurea-Based Treatment for Paediatric Patients with Sickle Cell Anaemia. (Press)
• Novartis, UNC study suggests mRNA structures are a common, untapped pool of drug targets (c&en)
• Imaging tool may optimize CAR T therapy for solid tumors (BioCentury)
• Kinase inhibitors: the road ahead (Nature)
• AACR preview: a lung cancer showdown (EP Vantage)
• Precision Medicine, Genome Sequencing, and Improved Population Health (JAMA)
• Docs more likely to prescribe opioids after pharma pay, study finds (Healthcare Dive)

• Genetic tests ordered by doctors race to market, while ‘direct-to-consumer’ tests hinge on FDA approval (STAT)
• AVATR Is An AI Smartphone Companion That Looks Out For You By Being You (Forbes)
• CARB-X backs HelixBind to develop sepsis test (Fierce) (Press)
• Noninvasive injection detection system iSenz completes validation trials, seeks commercialization (mobihealthnews)
• Parachute Health raises $5.5M to digitize 'archaic' medical equipment orders (mobihealthnews)
• Cook Medical touts win in IVC filter bellwether (MassDevice)
• Study: Wearable AI-powered biosensors show promise for HF detection (MassDevice)
• FDA tells Opternative to pull eye exam app from the market (Fierce)
• Bankrupt Laser Co. Hid Assets To Duck Court Judgments: Suit (Law360-$)
• Abbott Says Ex-Employee Should Pay For Dismissed FCA Suit (Law360-$)
• Mayo Clinic and Orbita forge partnership to expand health and wellness content reach (Medical Design & Outsourcing)
• Organogenesis launches new sizing option for PuraPly wound care device (Drug Delivery Business News)
• Clarify Medical Announces Issuance of Patent for Smartphone-Connected Phototherapy System (Press)
• OntarioMD Enters into New Partnership with the Ontario Telemedicine Network for Provincial Digital Health Delivery (Press)
• Houston hospitals used augmented reality to guide sinus surgery (Healthcare Dive)
• Reducing inappropriate joint replacements could save billions (Healthcare Dive)

• Cigna, Express Scripts To Face Tough Antitrust Review (Law360-$)
• FDA chief becomes point man on drug prices (The Hill)
• Why MyHealthEData Could Change the Pharmacy Field (PharmacyTimes)
• Pharmacy benefit managers lobby against rebate rule (Axios)
• Defense Sec. Mattis won't comment on Theranos fraud allegations (Axios)
• Here’s what needs to happen for digital health care information-sharing to actually become a successful reality (Recode)
• How ER Doctors Are Fighting The Opioid Crisis (Forbes)
• Lawyers: Elizabeth Holmes Could Still Serve Time In Prison (Forbes)
• Senator Murray Pushes FDA for Strong Rulemaking Process to Lower Nicotine Levels (Press)
• Alexander: 340B Program May Need Improvement to Fulfill Purpose of Helping Low-Income Patients (Press)
• US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say (Pink Sheet-$)
• Getting By On Their Own Supply: The Economics Of Hospitals As Generic Prescription Drug Manufacturers (Health Affairs)
• LISTEN: Theranos’s fate, biotech’s awkward SXSW, and a word on cow loogies (STAT)
• MITA Requests to participate in selection of participants for the NMQAAC (MITA)

• FDA Advisory Committee Calendar

• Siemens Healthineers Shares Jump After $5 Billion German IPO (Bloomberg)
• Ferring announces positive outcome of European Decentralised Procedure (DCP) for Testavan, a treatment for men with hypogonadism (Press)
• EMA Management Board: highlights of March 2018 meeting (EMA)

• Parliament to discuss SingPass disruption, student mental health and maid insurance (Channel NewsAsia)
• ViewRay wins Japanese approval for MRIdian Linac system (MassDevice)
• Foundation Medicine Advances Patient Access to Precision Medicine; Pursues Regulatory Approval for FoundationOne CDx in Japan (Press)
• Report of the PMDA-ATC Pharmacovigilance Seminar 2018 (PMDA)

• Higher Incomes, Rising Medical Costs, Create A Health Insurance Crisis In India (Bloomberg)
• Jagan DA case: Relief to pharma companies (Times of India)
• Dr Reddy's gets 4 observations from USFDA for Telangana plant (Economic Times)
• Over 17 lakh beneficiaries linked with maternity scheme, says Centre (Hindustan Times)

• Duro-K lead issue no cause for alarm (AJP)
• PreveCeutical Announces Incorporation of Australian Subsidiary to Support Ongoing Research Programs (Press)
• World’s first portable fingerprint drug test now available in Australia and New Zealand (Press)

• Costco under investigation by Ontario forensic team over drug company payments (CBC News)
• Pharmacare and the chaotic world of Canadian drug prices (iPolitics)
• Ipsen Announces Health Canada Approval of DYSPORT THERAPEUTIC (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults (Press)
• Government of Canada continues to invest in research to address global health threat of antimicrobial resistance (Press)

• Artificial Intelligence Is Infiltrating Medicine -- But Is It Ethical? (Forbes)
• This revolutionary healthcare firm producing affordable medical devices first started as a college project (YourStory)
• Digital Health Isn't A Social Science (Forbes)
• A Quiet Drug Problem Among the Elderly (NYT)
• The Future of Medicine From a Leader in Biosensors (Medscape)